What is MiNK Therapeutics, Inc.'s market cap?

MiNK Therapeutics, Inc. (INKT) has a market capitalization of $52.8M and trades on NASDAQ.

Who are MiNK Therapeutics, Inc.'s competitors?

MiNK Therapeutics, Inc.'s key competitors include Fate Therapeutics, Allogene Therapeutics, Adicet Bio, and others. These companies compete in similar markets and product categories.

Who does MiNK Therapeutics, Inc. partner with?

MiNK Therapeutics, Inc.'s notable partners include Agenus Inc., C-Further, Autonomous Therapeutics, and others.

Where is MiNK Therapeutics, Inc. headquartered?

MiNK Therapeutics, Inc. is headquartered in United States of America and employs approximately 37 people. It has been publicly traded since 2021.

MiNK Therapeutics, Inc.

INKT

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.

Market cap

$52.76M-20.0%

Table of contents

Earnings

Q1 2026 report

May 15, 2026

EPS-$0.57Beat by $0.20

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

EPS estimate-$0.60

Competitors

By market cap

Gilead Sciences$162.05B+15.3%

Bristol-Myers Squibb$127.75B+32.1%

Allogene Therapeutics$604.0M+87.9%

Artiva Biotherapeutics, Inc.$501.4M+595%

Fate Therapeutics$283.2M+90.1%

Adicet Bio, Inc.$75.3M+21.1%

MiNK Therapeutics, Inc.$52.8M-29.3%

GRI Bio, Inc.$2.5M-53.6%

By revenue growth

Gilead Sciences+3.5%

Bristol-Myers Squibb+1.8%

By net margin

Gilead Sciences30.99%+10.2pp

Bristol-Myers Squibb15.01%+3.8pp

Artiva Biotherapeutics, Inc.-79.28%—

Allogene Therapeutics-1,170,863.64%—

Profile

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company leverages the unique ability of iNKT cells to bridge innate and adaptive immunity, providing rapid cytolytic activity and durable memory responses without the need for HLA matching or lymphodepletion. Their platform aims to deliver scalable, cost-effective treatments for solid tumors, critical pulmonary immune failure, and graft-versus-host disease.

Competitive position

A pioneer in the industrialization of allogeneic iNKT cell therapies with vertically integrated manufacturing and clinical proof-of-concept in both oncology and pulmonary indications.

GeographiesUnited States

Customer segmentsPatients with refractory solid tumors, Patients with acute respiratory distress syndrome, Transplant recipients

Business modelR&D, Licensing, Biopharmaceutical Development

SuppliersHealthy donor PBMCs, cGMP-grade proprietary reagents, Specialized laboratory equipment, Intellectual property licensors

CustomersClinical trial sites, Academic medical centers, Strategic pharmaceutical collaborators

CountryUnited States of America

Listed2021

Employees37.0

CEOJennifer S. Buell

SectorHealthcare

IndustryBiotechnology

Websiteminktherapeutics.com

FilingsSEC EDGAR

Questions, answered.

What is MiNK Therapeutics, Inc.'s market cap?: MiNK Therapeutics, Inc. (INKT) has a market capitalization of $52.8M and trades on NASDAQ.
Who are MiNK Therapeutics, Inc.'s competitors?: MiNK Therapeutics, Inc.'s key competitors include Fate Therapeutics, Allogene Therapeutics, Adicet Bio, and others. These companies compete in similar markets and product categories.
Who does MiNK Therapeutics, Inc. partner with?: MiNK Therapeutics, Inc.'s notable partners include Agenus Inc., C-Further, Autonomous Therapeutics, and others.
Where is MiNK Therapeutics, Inc. headquartered?: MiNK Therapeutics, Inc. is headquartered in United States of America and employs approximately 37 people. It has been publicly traded since 2021.